“Powered by artificial intelligence integrating clinical, molecular and histopathology data, this new test provides more reliable prognostic information for breast cancer recurrence,” said lead author Joseph A. Sparano, MD, of the Icahn School of Medicine at Mount Sinai.
The new model, named IICM+, combines digitized pathology images of the tumor with features such as patient age, tumor size and grade, and molecular information from an expanded 42-gene panel. The team developed and independently validated IICM+ using tumor specimens and more than a decade of clinical outcomes from 4,429 participants in ECOG-ACRIN’s TAILORx breast cancer trial.